541 Digital assessment of hidradenitis suppurativa disease activity

Wiala, Antonia; Schöllhammer, M.; Singh, Sukhchain; Rappersberger, Klemens; Schnidar, H.; Posch, Christian

doi:10.1016/j.jid.2018.03.549

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By measuring the perfusion of the lesion, the latter technique can objectively measure the inflammatory status of a psoriasis plaque and thereby potential drug effects. For other skin diseases including hidradenitis suppurativa mobile and automated tools are available to determine erythema 22 . To assess disease severity more objectively in atopic dermatitis the digital eczema area and severity index (EASIdig) demonstrated good correlation to clinical scores 23 and even more accurate assessments using artificial intelligence are currently being developed.…”

Section: Cornerstone: Sensitive and Objective Clinical Endpointsmentioning

confidence: 99%

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology

Rißmann

Moerland

Doorn

2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Numerous new and innovative drugs are currently entering the dermatological market space. The dermatologist of the 20th century used to have a limited amount of pharmacological treatment options comprising mainly nonspecific drugs such as (topical) corticosteroids and methotrexate. This has changed tremendously in the last two decades when novel, targeted therapies became the new hallmark for the treatment of moderate to severe skin diseases. Risankizumab, for instance, is a monoclonal antibody selectively targeting interleukin 23 in chronic plaque psoriasis and is the 12th unique biologic drug that is registered in Europe and in the United States. Having these multiple, targeted treatment options available has greatly improved the flexibility and personalization of psoriasis care in clinical practice. However, such targeted treatment options are still under development for various other indications including atopic dermatitis, chronic urticaria, hidradenitis suppurativa, vitiligo, and alopecia areata.

show abstract

Section: Cornerstone: Sensitive and Objective Clinical Endpointsmentioning

confidence: 99%

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology

Rißmann

Moerland

Doorn

2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In addition to RID assessment, Scarletred Vision has recently been used in a broad range of dermatologic applications and skin conditions. For example it has been tested in the assessment of disease activity over time in patients with hidradenitis suppurativa [20], or in the prediction of a treatment response to topical Enstilar foam application in psoriasis [21]. Furthermore it has already been used as a machine learning based system for automated measurement and documentation of wound size, a semi-automatic machine learning psoriasis plaque grading system and an objective method for allergy and substance testing preferentially in the course of pre-clinical and clinical drug development [22].…”

Section: Discussionmentioning

confidence: 99%

Testing the feasibility of augmented digital skin imaging to objectively compare the efficacy of topical treatments for radiodermatitis

et al. 2019

View full text Add to dashboard Cite

Introduction Radiation-induced dermatitis (RID) is routinely graded by visual inspection. Inter-observer variability makes this approach inadequate for an objective assessment of the efficacy of different topical treatments. In this study we report on the first clinical application of a new image-analysis tool developed to measure the relevant effects quantitatively and to compare the effects of two different topical preparations used to treat RID. Materials and methods After completion of radiotherapy, RID was retrospectively assessed in 100 white female breast cancer patients who had received adjuvant breast irradiation. Of these patients, 34 were treated with R1&R2, a Lactokine-fluid derived from milk proteins, and 66 were treated with Bepanthen. In addition RID was graded independently by two experienced radiation oncologists in accordance with the Common Terminology Criteria for Adverse Events (CTCAE). For quantitative evaluation, the irradiated breast and the non-irradiated contralateral breast were photographed in a standardized manner including a color reference card. For analysis, all images were converted into the color space L*a*b* and mean values were calculated for each of the color parameters. Results The CTCAE-based grading revealed statistically significant inter-observer variability in the scoring of RID Grades 1, 2 and 3 (p<0.001). A difference between the two topical products could not be observed with visual inspection. By using augmented image analysis methods a statistically significant increase in a*-values (mean 4.15; 95%CI: 5.97–2.33, p<0.001) in patients treated with R1&R2 indicated more intense reddening. Digital subtraction was used to eliminate differences in individual baseline skin tone to generate a new, low-scatter parameter (ΔSEV). Conclusions Visual CTCAE-based evaluation of RID was not suitable for assessing the efficacy of the skin treatment products. In contrast, the novel image analysis enabled a quantitative evaluation independent of skin type and baseline skin tone in our cohort suggesting that augmented image analysis may be a suitable tool for this type of investigation. Prospective studies are needed to validate our findings.

show abstract

541 Digital assessment of hidradenitis suppurativa disease activity

Cited by 2 publications

References 0 publications

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology

Blueprint for mechanistic, data‐rich early phase clinical pharmacology studies in dermatology

Testing the feasibility of augmented digital skin imaging to objectively compare the efficacy of topical treatments for radiodermatitis

Contact Info

Product

Resources

About